https://stockhub.co/index.php?action=history&feed=atom&title=AB_Science_S.A. 2026-05-07T03:57:36Z Revision history for this page on the wiki MediaWiki 1.43.5 https://stockhub.co/index.php?title=AB_Science_S.A.&diff=52201&oldid=prev 2022-08-16T03:32:34Z

<p>Created page with &quot;== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; == AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer&#039;s, severe asthma, and mastocytosis diseases,...&quot;</p> <p><b>New page</b></p><div>== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; ==<br /> <br /> AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer&#039;s, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.<br /> <br /> == References and notes == <br /> [[Category:Thesis]]<br /> __INDEX__</div>

>Paris